Method of treatment based on polymorphisms of the KCNQ1 gene
The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
1. A method of administering iloperidone or a metabolite thereof to treating a human individual the method comprising:
determining or having determined the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 ; and
in the case that the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 is associated with an increased risk of QT prolongation, administering to the individual a first quantity of iloperidone or a metabolite thereof, and
in the case that the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 is not associated with an increased risk of QT prolongation, administering to the individual a second quantity of iloperidone or a metabolite thereof, wherein the first quantity is less than the second quantity,
wherein a KCNQ1 genotype of CC at position 78927 of SEQ. ID. 1 is associated with an increased risk of QT prolongation, and the KCNQ1 genotype not associated with an increased risk of QT prolongation is non-CC at position 78927 of SEQ. ID. 1.
2. The method of claim 1 , wherein the method comprises administering iloperidone to the individual.
3. The method of claim 1 , wherein the method comprises administering a metabolite of iloperidone to the individual, wherein the metabolite is 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-y1)-1 -piperidinyl] propoxy]-3 -methoxyphenyl]ethanol.
4. The method of claim 1 , further comprising:
determining or having determined at least a portion of the patient's CYP2D6 genotype, in the case that the individual's CYP2D6G1846A genotype is AA or GA or the individual's CYP2D6C100T genotype is TT or CT, and the individual has a KCNQ1 genotype of CC at position 78927 of SEQ. ID. 1, administering to the individual the first quantity of iloperidone or the metabolite thereof, and in the case that the individual's CYP2D6G1846A genotype is GG or the individual's CYP2D6C100T genotype is CC, and the individual's KCNQ1 genotype is non-CC at position 78927 of SEQ. ID. 1, administering to the individual the second quantity of iloperidone or the metabolite thereof.
5. The method of claim 1 , wherein the human individual is suffering from at least one condition selected from a group consisting of:
schizophrenia, including paranoid schizophrenia, catatonic schizophrenia, disorganized schizophrenia, undifferentiated schizophrenia, and residual schizophrenia; schizoaffective disorder, depression, bipolar mania/depression, cardiac arrythmia, Tourette's Syndrome, a psychotic disorder, including brief psychotic disorder, a psychotic disorder not otherwise specified, a psychotic disorder due to a general medical condition, and a substance-induced psychotic disorder; a delusional disorder, and schizophreniform disorder.
6. The method of claim 1 , wherein the second quantity of iloperidone is 24 mg/day.
7. The method of claim 1 , wherein the KCNQ 1 genotype not associated with an increased risk of QT prolongation is AC or AA at position 78927 of SEQ ID NO: 1.
8. A method of treating a human individual with iloperidone or a metabolite thereof, the method comprising:
characterizing an expression product of the individual's KCNQ1 gene; and
in the case that the characterized expression product corresponds to a KCNQ1 genotype of CC at position 78927 of SEQ. ID. 1, administering to the individual a first quantity of iloperidone or a metabolite thereof, and
in the case that the characterized expression product corresponds to a KCNQ1 genotype of non-CC at position 78927 of SEQ. ID. 1, administering to the individual a second quantity of iloperidone or a metabolite thereof,
wherein the first quantity is less than the second quantity.
9. The method of claim 8 , further comprising:
characterizing an expression product of the individual's CYP2D6 gene; and
determining whether the characterized expression product corresponds to a CYP2D6 polymorphism selected from a group consisting of: CYP2D6G1846A and CYP2D6C100T.
10. The method of claim 8 , wherein the second quantity of iloperidone is 24 mg/day.
11. The method of claim 8 , wherein the non-CC KCNQ1 genotype at position 78927 of SEQ ID NO: 1 is AC or AA.
12. A method of administering iloperidone or a metabolite thereof to a human individual suffering from long QT syndrome (LQTS), the method comprising:
determining or having determined the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1; and
administering to the individual a quantity of the iloperidone or the metabolite thereof based on the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1,
wherein a first quantity is administered to the individual in a case in which the individual has a KCNQ1 genotype of CC at position 78927 of SEQ. ID. 1, and a second quantity is administered to the individual in a case in which the individual has a KCNQ1 genotype that is non-CC at position 78927 of SEQ. ID. 1.
13. The method of claim 12 , further comprising:
determining or having determined the individual's CYP2D6 genotype; and
determining whether the individual's CYP2D6 genotype corresponds to a CYP2D6 polymorphism selected from a group consisting of: CYP2D6G1846A and CYP2D6C100T.
14. The method of claim 12 , wherein the second quantity of iloperidone is 24 mg/day.
15. The method of claim 12 , wherein the non-CC KCNQ1 genotype at position 78927 of SEQ ID NO: 1 is AC or AA.